Full Text PA-97-078 INFLAMMATION IN ASTHMA AND ALLERGY NIH GUIDE, Volume 26, Number 24, July 25, 1997 PA NUMBER: PA-97-078 P.T. 34 Keywords: Asthma Inflammation Hypersensitivity National Institutes of Health PURPOSE The purpose of this asthma and allergy research Program Announcement (PA) is to inform the scientific community of the interests of NIH Institutes in stimulating a wide range of basic and clinical studies to: characterize the role of tissue inflammation in the pathogenesis of asthma and allergic diseases; identify factors responsible for the initiation and maintenance of inflammation in asthma and allergic diseases; and, based on this knowledge, develop new and improved approaches to treat and prevent these disorders. The funding mechanisms to be used to support research under this PA are R01s and R29s. HEALTHY PEOPLE 2000 Each NIH PA addresses one or more of 22 Health Promotion and Disease Prevention priority areas identified. These areas can be found via the WWW at URL: http://www/crisny.org/health/us/health7.html ELIGIBILITY Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for FIRST awards (R29). Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT Traditional research project grant (R01) and FIRST award (R29) applications may be submitted in response to this program announcement. Applications for R01 grants may request up to five years of support and applications for R29 grants must request five years of support. Responsibility for the planning, direction, and execution of the proposed research for all applicable mechanisms of support will be solely that of the applicant. RESEARCH OBJECTIVES Background This PA will support studies of the underlying mechanisms of inflammation in asthma and allergic diseases. Chronic inflammation of the airways is now recognized as a primary factor in the development of asthma and anti-inflammatory medications, especially inhaled steroids, have become a mainstay of asthma therapy. However, even medically well-controlled asthmatics are subject to exacerbations that are difficult to treat, and it is likely that insights into the pathogenesis of inflammation will lead to more effective and safer therapies for asthma and allergic diseases. Research Objectives and Scope Recent studies have demonstrated the importance of previously unrecognized pathways leading to tissue inflammation in asthma and allergic diseases. For example, "upper" respiratory viral infections were recently shown to induce widespread airway inflammation in humans and are now known to be the most common cause of severe asthmatic exacerbations. However, the cellular and molecular mechanisms by which viruses elicit airway inflammation are largely unknown. In epidemiologic and genetic studies, investigators have identified a number of promising candidate genes and genetic loci that are related to asthma, airway hyperresponsiveness, and atopy. In several instances, the candidate genes encode proteins known to be involved in the evolution of inflammatory responses. Thus, genetic studies may help to identify new therapeutic targets for asthma and allergic diseases. In addition, genetic approaches may ultimately enable clinicians to target individual therapies more selectively in specific patient populations and to develop mechanism-based strategies for primary prevention. Certain technological advances and recently developed tools can also be expected to facilitate progress in these areas. These include: (1) the ability to directly visualize the airways by fiberoptic bronchoscopy and to routinely obtain bronchoalveolar lavage fluids and inflammatory cells for study; (2) the advent of better animal models that more closely mimic the altered immune function in human asthma; and (3) the availability of transgenic and gene knockout animals to test the importance of specific mediators, receptors, and signaling pathways in the induction of tissue inflammation. Examples of research topics of interest include, but are not limited to, the following: Allergic Mechanisms o identification and characterization of genes that regulate the production of IgE and the clinical expression of asthma and atopy; o structural analysis and recombinant molecular engineering of allergen epitopes to develop new approaches for immune modulation; Non-Allergic Mechanisms o studies to define the immune mechanisms of virus-mediated airway inflammation and bronchial hyperactivity in asthma; o studies on the role of environmental agents, including aromatic hydrocarbons, ozone, and nitrogen dioxide, in the induction of airway inflammation and their role in asthma; Combined Allergic and Non-Allergic Mechanisms o studies of chemokines in asthma; o studies to determine the mechanisms that lead to differential induction of Th1 and Th2 responses, and development of strategies to manipulate Th1 and Th2 responses for treatment or prevention of asthma and allergic diseases; o studies on the induction and primary prevention of asthma; and o research on factors that control the persistence or cessation of inflammation in the context of asthma and allergic diseases. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS See NIH Guide of March 18, 1994 for requirements for inclusion of Women and Minorities in research. It is available via the WWW at URL: http://www.nih.gov/grants (select NIH Guide for Grants and Contracts). APPLICATION PROCEDURES Applications are to be submitted on the grant application for PHS 398 (rev. 5/95) and will be accepted on the standard application deadlines as indicated on the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Extramural Outreach and Information, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, email: asknih@odrockm1.nih.gov. The PHS 398 application kit can be accessed from the World Wide Web at the following URL: http://www.nih.gov/grants/funding/phs398/phs398.html For purposes of identification and processing, item 2 on the face page of the application must be marked "YES". The PA number, the PA title must be typed in section 2. The completed, signed original and five legible, single-sided copies of the application must be sent or delivered to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817-7710 (for express/courier service) R29 applications must include at least three (3) sealed letters of reference attached to the face page of the original application. FIRST applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. ALL APPLICANTS REQUESTING $500,000 OR MORE IN ANNUAL DIRECT COSTS. The NIH Policy Update on Acceptance for Review of Unsolicited Applications that Request More Than $500,000 Direct Cost for Any One Year applies to applications in response to this PA. The Policy Update was published in the NIH Guide for Grants and Contracts, Volume 25, No. 14, May 3, 1996, and became effective June 1, 1996. Potential applicants must contact the appropriate program staff listed in INQUIRIES below to initiate clearance processes for acceptance of their applications. Applicants from institutions that have a General Clinical Research Centers (GCRC) funded by the NIH National Center for Research Resources may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from the GCRC Program Director must be included in the application material. REVIEW CONSIDERATIONS Review Procedures Applications will be assigned to NIH Institutes and Centers on the basis of established PHS referral guidelines. Upon receipt, applications will be reviewed for completeness by the NIH Division of Research Grants. Incomplete applications will be returned to the applicant without further consideration. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council. Review Criteria The five criteria to be used in the evaluation of grant applications are listed below. The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. The reviewers will be asked to comment on the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered by the reviewers in assigning the overall score weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. 1. SIGNIFICANCE. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? 2. APPROACH. Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? 3. INNOVATION. Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? 4. INVESTIGATOR. Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? 5. ENVIRONMENT. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? The initial review group will also examine: the appropriateness of proposed project budget and duration; the adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research and plans for the recruitment and retention of subjects; the provisions for the protection of human and animal subjects; and the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other favorably recommended applications. The following will be considered when making funding decisions: quality of the proposed project as determined by peer review, program balance, and availability of funds. SPONSORS AND INQUIRIES Each sponsoring Institute/Center is identified below. A staff contact for electronic and telephone is listed and inquiries regarding programmatic (research scope, eligibility and responsiveness) issues are encouraged. The opportunity to clarify any issues or answer questions from potential applicants is welcome. National Institute of Allergy and Infectious Diseases Daniel Rotrosen, M.D. Telephone: (301) 496-8974 Fax: (301) 402-0175 Email: dr17g@nih.gov National Heart, Lung, and Blood Institute Susan Banks-Schlegel, Ph.D. Telephone: (301) 435-0202 Fax: (301) 480-3557 Email: Susan_Banks-Schlegel@nih.gov National Institute of Environmental Health Sciences George S. Malindzak, Jr., Ph.D. Telephone: (919) 541-3289 Telefax: (919) 541-2843 Email Address: gm26f@nih.gov AUTHORITY AND REGULATIONS Research under this announcement will be supported under program cited in the Catalog of Federal Assistance (CFDA). The PHS portion of the CFDA is available at URL: http://odphp.osophs.dhhs.gov/cfda/index.htm Awards will be administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems review. The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |